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BACKGROUND
On the basis of data from a phase 2 trial that compared the checkpoint inhibitor 
ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in 
patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a 
dose of 10 mg per kilogram in patients who had undergone complete resection of 
stage III melanoma.
METHODS
After patients had undergone complete resection of stage III cutaneous melanoma, 
we randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram 
(475 patients) or placebo (476) every 3 weeks for four doses, then every 3 months 
for up to 3 years or until disease recurrence or an unacceptable level of toxic ef-
fects occurred. Recurrence-free survival was the primary end point. Secondary end 
points included overall survival, distant metastasis–free survival, and safety.
RESULTS
At a median follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 
40.8% in the ipilimumab group, as compared with 30.3% in the placebo group 
(hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 
0.89; P<0.001). The rate of overall survival at 5 years was 65.4% in the ipilimumab 
group, as compared with 54.4% in the placebo group (hazard ratio for death, 0.72; 
95.1% CI, 0.58 to 0.88; P = 0.001). The rate of distant metastasis–free survival at 
5 years was 48.3% in the ipilimumab group, as compared with 38.9% in the pla-
cebo group (hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 
0.92; P = 0.002). Adverse events of grade 3 or 4 occurred in 54.1% of the patients 
in the ipilimumab group and in 26.2% of those in the placebo group. Immune-
related adverse events of grade 3 or 4 occurred in 41.6% of the patients in the 
ipilimumab group and in 2.7% of those in the placebo group. In the ipilimumab 
group, 5 patients (1.1%) died owing to immune-related adverse events.
CONCLUSIONS
As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg 
per kilogram resulted in significantly higher rates of recurrence-free survival, 
overall survival, and distant metastasis–free survival than placebo. There were 
more immune-related adverse events with ipilimumab than with placebo. (Funded 
by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00636168, and EudraCT 
number, 2007-001974-10.)
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Ipilimumab, a fully human monoclo-nal antibody that blocks cytotoxic T-lympho-cyte antigen 4 (CTLA-4) to augment anti-
tumor immune responses, was approved by the 
Food and Drug Administration (FDA) and the 
European Medicines Agency in 2011 at a dose of 
3 mg per kilogram of body weight for the treat-
ment of advanced melanoma.1,2 On the basis of 
data from a phase 2 trial that indicated the po-
tential for a dose of 10 mg per kilogram to have 
higher efficacy than the dose of 0.3 mg or 3 mg 
per kilogram in patients with advanced mela-
noma, although at a cost of more toxic effects,3,4 
we conducted a phase 3 trial (European Organi-
zation for Research and Treatment of Cancer 
[EORTC] 18071) of ipilimumab at a dose of 10 mg 
per kilogram in patients who had resected re-
gional lymph node–positive (stage III) melanoma 
with a high risk of recurrence.
The likelihood of systemic metastatic disease 
among patients with stage III melanoma corre-
lates closely with microscopic versus palpable 
nodal disease and with the number of positive 
nodes.5-7 The population of patients with stage III 
melanoma is heterogeneous, with disease-specific 
survival rates of 78% among patients with stage 
IIIA disease, 59% among those with stage IIIB 
disease, and 40% among those with stage IIIC 
disease.5-7 Even within the population of patients 
who have sentinel node–positive cancer, hetero-
geneity is remarkable and correlates closely with 
tumor load in the sentinel node (as defined by 
the Rotterdam criteria; see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org).8-10 Patients with a metastasis 
of more than 1 mm in the greatest dimension 
have a significantly higher risk of recurrence or 
death than those with a metastasis of 1 mm or 
less in the greatest dimension.8-10
We previously reported the primary results of 
the EORTC 18071 phase 3 trial in which we 
compared adjuvant ipilimumab with placebo in 
patients with resected stage III melanoma.11 At a 
median follow-up of 2.7 years, adjuvant ipilimu-
mab was associated with significantly prolonged 
recurrence-free survival, the primary end point, 
as compared with placebo (hazard ratio, 0.75; 
P = 0.001). The results on the global health scale, 
which was the primary health-related quality-of-
life end point, were not affected by ipilimumab.12 
Approval from the FDA was granted in 2015 on 
the basis of the results of this trial. The effect of 
ipilimumab on overall survival and distant metas-
tasis–free survival is important, given that the 
only other approved systemic therapy in the con-
text of adjuvant therapy, interferon alfa, has a 
marginal effect on overall survival.13-15 Here, we 
report, at a median follow-up of 5.3 years, the 
efficacy of adjuvant therapy with ipilimumab on 
all survival end points in patients with high-risk 
stage III melanoma after complete lymph-node 
dissection.
Me thods
Patients
Eligible patients were 18 years of age or older 
with histologically confirmed cutaneous mela-
noma that was metastatic to regional lymph 
nodes. According to the American Joint Commit-
tee on Cancer 2009 classification, patients had 
stage IIIA melanoma (patients with N1a cancer 
[i.e., only one node involved with micrometasta-
sis] had to have at least one metastasis measur-
ing >1 mm in the greatest dimension) or stage 
IIIB or IIIC melanoma with no in-transit metas-
tases (i.e., growing >2 cm away from the primary 
tumor but before reaching the nearest lymph 
node).2 Complete regional lymphadenectomy was 
required within 12 weeks before randomization. 
Exclusion criteria included an Eastern Coopera-
tive Oncology Group (ECOG) performance-status 
score of more than 1 (on a scale from 0 to 5, 
with higher numbers indicating greater disabil-
ity), autoimmune disease, uncontrolled infection, 
substantial cardiovascular disease (New York 
Heart Association functional class III or IV), a 
lactate dehydrogenase level of more than 2 times 
the upper limit of the normal range, use of sys-
temic glucocorticoids, and previous systemic 
therapy for melanoma.
Trial Design and Regimen
In this randomized, double-blind, phase 3 trial, 
patients were enrolled at 99 centers in 19 coun-
tries. Registration was done centrally at the 
EORTC headquarters. A central interactive voice-
response system was used for randomization 
and was based on a minimization technique.16 
Randomization was stratified according to dis-
ease stage (stage IIIA vs. stage IIIB vs. stage IIIC 
with one, two, or three positive nodes vs. stage 
IIIC with four or more positive nodes) and geo-
graphic region (North America, Europe, or Aus-
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tralia). Local pharmacists, who were aware of 
the trial-group assignments, performed the ran-
domization. Clinical investigators and persons 
collecting or analyzing the data were unaware of 
the trial-group assignments.
Patients were randomly assigned in a 1:1 ratio 
to receive an intravenous infusion of ipilimumab 
at a dose of 10 mg per kilogram or placebo every 
3 weeks for four doses, then every 3 months for 
up to 3 years or until disease recurrence, an 
unacceptable level of toxic effects, a major pro-
tocol violation, or withdrawal of consent (Fig. S1 
in the Supplementary Appendix). The rules re-
garding the withholding of a dose of ipilimumab 
or placebo and the management of immune-
related adverse events are detailed in the full 
trial protocol, available at NEJM.org.
The primary end point was recurrence-free 
survival. The secondary end points included over-
all survival, distant metastasis–free survival, safe-
ty, and health-related quality of life.
Assessments
Patients in the two trial groups were assessed for 
recurrence and distant metastases every 3 months 
during the first 3 years and every 6 months 
thereafter. Physical examination and radiogra-
phy of the chest, computed tomography, mag-
netic resonance imaging, or other imaging tech-
niques were performed if indicated. Recurrence 
or metastatic lesions had to be histologically 
confirmed whenever possible. The first date 
when recurrence was observed was used in the 
analysis, regardless of the method of assessment.
Recurrence-free survival was defined as the 
time from randomization until the date of first 
recurrence (local, regional, or distant metasta-
sis) or death from any cause. Overall survival 
was defined as the time from randomization 
until death from any cause. Distant metastasis–
free survival was defined as the time from ran-
domization until the date of the first distant 
metastasis or death from any cause.
Data on adverse events were collected for each 
group with the use of the Common Terminology 
Criteria for Adverse Events, version 3.0. Immune-
related adverse events were determined pro-
grammatically from a prespecified list of terms 
from the Medical Dictionary for Regulatory Activities 
(MedDRA), which was updated according to each 
new version of MedDRA.
Resolution of an immune-related adverse event 
of grade 3 or 4 was defined as an improvement 
to grade 1 or less. The grade 3 or 4 event with 
the longest time to resolution was selected for 
inclusion in the analysis. If the grade 3 or 4 event 
did not resolve, follow-up was censored at the 
last known date that the patient was alive. Simi-
lar analyses were repeated for immune-related 
adverse events of grade 2 through 5.
Trial Oversight
The trial protocol was approved by the EORTC 
protocol-review committee and by independent 
ethics committees. The trial was conducted in 
accordance with the Declaration of Helsinki and 
with Good Clinical Practice guidelines as defined 
by the International Conference on Harmonisa-
tion. All the patients provided written informed 
consent.
The trial was funded and sponsored by Bristol-
Myers Squibb. The trial was designed by the writ-
ing committee (the trial coordinator [the first 
author], the EORTC headquarters team, and a 
representative of the sponsor). Data were collect-
ed and computerized at the EORTC headquarters 
and were copied to the sponsor after the data-
base lock. Data were analyzed independently at 
the EORTC headquarters and by the sponsor. 
The manuscript was written by two of the aca-
demic authors (the first and penultimate authors), 
all the coauthors commented on it, and editorial 
assistance was provided by professional medical 
writers paid by the sponsor. The two specified 
academic authors made the decision to submit 
the manuscript for publication, with the consent 
of all the other authors. The authors vouch for 
accuracy and completeness of the data and 
analyses and confirm the adherence of the trial 
to the protocol.
An independent review committee, whose 
members were unaware of the trial-group assign-
ments, assessed disease status and date of recur-
rence. An independent data and safety monitor-
ing board assessed the safety and efficacy data 
every 6 months, without formal interim analy-
ses. Only at the time of the final analysis of re-
currence-free survival were interim analyses of 
overall survival and distant metastasis–free sur-
vival performed by an independent statistician, 
and the results were forwarded to members of 
the data and safety monitoring board. On-site 
source-data verification was provided by a clini-
cal research organization.
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Statistical Analysis
We planned for the trial to include 950 patients. 
In the initial protocol, we calculated that a total 
of 491 deaths would be required in order to pro-
vide the trial with 85% power to detect a differ-
ence in the 4.5-year overall survival rates of 42.3% 
in the placebo group and 52.0% in the ipilimu-
mab group, corresponding to a hazard ratio for 
death of 0.76. Owing to an improvement in 
outcomes after recurrence (because of a change 
in the treatment landscape for patients with 
melanoma), it was decided, by means of a proto-
col amendment, to perform the final analyses 
for overall survival and distant metastasis–free 
survival at the same time. Given the 506 events 
of distant metastasis or death and 376 deaths at 
the clinical cutoff date (January 31, 2016), it was 
recomputed (with the use of a Lan–DeMets alpha-
spending function) that the final analyses of 
overall survival and distant metastasis–free sur-
vival be performed at two-sided alpha levels of 
0.049 and 0.042, respectively, so the confidence 
interval for the hazard ratio of the group com-
parison regarding these end points was set at 
95.1% and 95.8%, respectively; the statistical 
power was 75.8% and 89.4%, respectively. The 
statistical analysis plan (available with the trial 
protocol) indicated that in order to preserve the 
alpha error, a hierarchical-testing approach would 
be applied after the analysis of the primary end 
point of recurrence-free survival. Overall survival 
was tested first, followed by distant metastasis–
free survival. For the subgroup analysis, the es-
timated hazard ratio was plotted along with its 
99% confidence interval.
The main analyses of the efficacy end points 
included all the patients who had undergone ran-
domization, according to the intention-to-treat 
principle. The safety profile was assessed in pa-
tients who received at least one dose of the ran-
domly assigned regimen. Details of the statisti-
cal methods are provided in the Supplementary 
Appendix.
R esult s
Patients and Trial Regimen
From July 2008 through August 2011, a total of 
951 patients underwent randomization: 475 pa-
tients were assigned to the ipilimumab group 
and 476 to the placebo group. The characteris-
tics at baseline were similar between the two 
randomized groups (Table 1).
Six patients (4 patients in the ipilimumab 
group and 2 in the placebo group) did not start 
the randomly assigned regimen (Fig. S2 in the 
Supplementary Appendix). The median number 
of doses that were received was 4 doses (inter-
quartile range, 3 to 8) in the ipilimumab group 
and 8 (interquartile range, 4 to 16) in the placebo 
group. At least 1 maintenance dose (dose 5 and 
beyond) was received by 198 of 471 patients 
(42.0%) in the ipilimumab group and by 332 of 
474 (70.0%) in the placebo group.
Of 471 patients who started ipilimumab, 251 
(53.3%) discontinued treatment owing to an ad-
verse event (including 182 patients [38.6%] who 
discontinued within 12 weeks after randomiza-
tion); in 240 patients (51.0%), the event was 
considered by the investigators to be drug-related. 
Among 474 patients who received placebo, 22 
(4.6%) discontinued treatment owing to an ad-
verse event. A total of 135 patients (28.7%) in the 
ipilimumab group discontinued treatment be-
cause of disease recurrence, as compared with 
282 (59.5%) in the placebo group. A total of 63 
patients (13.4%) in the ipilimumab group and 
143 (30.2%) in the placebo group completed the 
3-year treatment period (Fig. S2 in the Supple-
mentary Appendix).
The overall median follow-up was 5.3 years. 
The median follow-up was 5.3 years in the ipi-
limumab group and 5.4 years in the placebo 
group.
Efficacy and Postprotocol Treatment
In this updated analysis, the rate of recurrence-
free survival at 5 years was 40.8% in the ipilimu-
mab group, as compared with 30.3% in the 
placebo group (hazard ratio for recurrence or 
death, 0.76; 95% confidence interval [CI], 0.64 to 
0.89; P<0.001) (Fig. 1A). The overall significant 
prolongation of recurrence-free survival that was 
due to adjuvant ipilimumab appeared to be con-
sistent across subgroups (Fig. S3A in the Sup-
plementary Appendix), but the trial was not 
powered to provide robust subgroup analysis. 
Ipilimumab appeared to be helpful in patients 
with microscopic involvement (hazard ratio vs. 
placebo, 0.68) and in patients with macroscopic 
involvement (hazard ratio, 0.84) (Fig. S3B and 
S3C in the Supplementary Appendix).
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Among the 264 patients in the ipilimumab 
group who had recurrence or died, 194 had 
received at least one postprotocol treatment (Ta-
ble 2). These treatments included ipilimumab 
(24 patients), anti–programmed death 1 (PD-1) 
therapy (24 patients), and a BRAF inhibitor (63 
patients). Among the 323 patients in the placebo 
group who had recurrence or died, 250 received 
postprotocol treatment: ipilimumab (76 patients), 
anti–PD-1 therapy (30 patients), and a BRAF in-
hibitor (88 patients). Overall survival after dis-
ease recurrence was similar in the two trial 
groups (hazard ratio for ipilimumab vs. placebo, 
0.89), which suggests that the difference in re-
Characteristic
Ipilimumab 
(N = 475)
Placebo 
(N = 476)
Sex — no. (%)
Male 296 (62.3) 293 (61.6)
Female 179 (37.7) 183 (38.4)
Age
Median (range) — yr 51 (20–84) 52 (18–78)
Distribution — no. (%)
<50 yr 214 (45.1) 211 (44.3)
51 to <65 yr 180 (37.9) 178 (37.4)
≥65 yr 81 (17.1) 87 (18.3)
Disease stage — no. (%)
At randomization
IIIA 98 (20.6) 98 (20.6)
IIIB 182 (38.3) 182 (38.2)
IIIC with 1–3 positive lymph nodes 122 (25.7) 121 (25.4)
IIIC with ≥4 positive lymph nodes 73 (15.4) 75 (15.8)
According to AJCC 2002 criteria†
IIIA 98 (20.6) 88 (18.5)
IIIB 213 (44.8) 207 (43.5)
IIIC with 1–3 positive lymph nodes 69 (14.5) 83 (17.4)
IIIC with ≥4 positive lymph nodes 95 (20.0) 98 (20.6)
Type of lymph‑node involvement — no. (%)†
Microscopic 210 (44.2) 193 (40.5)
Macroscopic 265 (55.8) 283 (59.5)
No. of positive lymph nodes on pathological testing — no. (%)†
1 217 (45.7) 220 (46.2)
2 or 3 163 (34.3) 158 (33.2)
≥4 95 (20.0) 98 (20.6)
Ulceration — no. (%)†
Yes 197 (41.5) 203 (42.6)
No 257 (54.1) 244 (51.3)
Unknown 21 (4.4) 29 (6.1)
*  There were no significant between‑group differences in the characteristics listed here. Percentages may not total 100 
because of rounding. AJCC denotes American Joint Committee on Cancer.
†  Data were from case‑report forms.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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currence-free survival would persist in terms of 
overall survival.
The overall survival rate at 5 years was 65.4% 
(95% CI, 60.8 to 69.6) in the ipilimumab group, 
as compared with 54.4% (95% CI, 49.7 to 58.9) in 
the placebo group. Overall survival was signifi-
cantly longer in the ipilimumab group than in 
the placebo group (hazard ratio for death from 
any cause, 0.72; 95.1% CI, 0.58 to 0.88; P = 0.001) 
(Fig. 1B). The prolongation of overall survival 
with ipilimumab was generally consistent across 
subgroups (Fig. 2, and Fig. S4 in the Supplemen-
tary Appendix). The rate of distant metastasis–
free survival at 5 years was higher in the ipilimu-
mab group than in the placebo group (48.3% vs. 
Figure 1. Kaplan–Meier Estimates of Recurrence-free 
Survival (RFS), Overall Survival, and Distant Metastasis–
free Survival (DMFS).
Panel A shows the Kaplan–Meier estimate of recurrence‑
free survival according to the independent review com‑
mittee. In the ipilimumab group, local or regional recur‑
rence was reported in 96 patients, distant metastasis or 
death due to melanoma in 157, and death due to another 
cause or an unknown cause in 11. In the placebo group, 
local or regional recurrence was reported in 114 patients, 
distant metastasis or death due to melanoma in 204, 
and death due to another cause or an unknown cause 
in 5. All the statistical comparisons shown here were 
stratified according to the disease stage as provided at 
randomization. In the comparison that was stratified 
according to the disease stage as given on case‑report 
forms, the hazard ratio for recurrence or death was 
0.77 (95% CI, 0.65 to 0.90; P = 0.001). In a per‑protocol 
analysis of the comparison that was stratified accord‑
ing to the disease stage as given at randomization, the 
hazard ratio was 0.77 (95% CI, 0.65 to 0.91; P = 0.002). 
Panel B shows the Kaplan–Meier estimate of overall 
survival. Because the number of patients with a follow‑
up of more than 7 years was too small, the estimated 
median overall survival was either unreliable or not 
reached. In the comparison that was stratified accord‑
ing to the disease stage as given on case‑report forms, 
the hazard ratio for death was 0.73 (95.1% CI, 0.60 to 
0.90; P = 0.003). In a per‑protocol analysis of the com‑
parison stratified according to the disease stage as given 
at randomization, the hazard ratio was 0.72 (95.1% CI, 
0.58 to 0.89; P = 0.002). Panel C shows the Kaplan–Meier 
estimate of distant metastasis–free survival according 
to the independent review committee. In the compari‑
son that was stratified according to the disease stage 
as given on the case‑report forms, the hazard ratio for 
distant metastasis or death was 0.77 (95.8% CI, 0.65 to 
0.93; P = 0.004). In a per‑protocol analysis of the compar‑
ison stratified according to the disease stage as given 
at randomization, the hazard ratio was 0.76 (95.8% CI, 
0.63 to 0.91; P = 0.003).
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38.9%; hazard ratio for distant metastasis or 
death, 0.76; 95.8% CI, 0.64 to 0.92; P = 0.002) 
(Fig. 1C).
Safety
Among the 471 patients who received ipilimu-
mab, 465 (98.7%) had an adverse event of any 
grade, with grade 3 or 4 adverse events occur-
ring in 255 patients (54.1%); among the 474 pa-
tients who received placebo, 432 (91.1%) had an 
adverse event of any grade, with grade 3 or 4 ad-
verse events occurring in 124 (26.2%) (Table S1 
in the Supplementary Appendix). Immune-related 
adverse events during the trial were more fre-
quent with ipilimumab than with placebo (Ta-
ble 3). Immune-related adverse events of grade 3 
or 4 occurred in 41.6% of the patients in the 
ipilimumab group and in 2.7% of those in the 
placebo group. The most common immune-related 
adverse events of grade 3 or 4 in the ipilimumab 
group were gastrointestinal (in 16.1% of the 
patients), hepatic (in 10.8%), and endocrine (in 
7.9%). The median time to the onset of immune-
related adverse events of grade 2 through 5 during 
the trial ranged from 4.0 weeks (skin immune-
related adverse events) to 13.1 weeks (neurologic 
immune-related adverse events) (Table S2 in the 
Supplementary Appendix). Endocrine immune-
related adverse events of grade 2 through 5 re-
solved in 51.5% of the patients, and the median 
time to resolution was 54.3 weeks. The majority 
(82 to 97%) of all other immune-related adverse 
events of grade 2, 3, or 4 resolved, and the median 
time to resolution ranged from 4.0 to 8.0 weeks.
Five patients (1.1%) died owing to adverse 
events that were attributed to ipilimumab: three 
patients died from colitis (two patients with intes-
tinal perforation), one patient from myocarditis, 
and one patient from multiorgan failure that was 
associated with the Guillain–Barré syndrome. 
These deaths occurred before the start of main-
tenance therapy. Of these patients, four had re-
ceived glucocorticoids and one anti–tumor necro-
sis factor antibodies.
Discussion
In this randomized, phase 3 trial involving pa-
tients with resected, high-risk stage III melano-
ma, ipilimumab at a dose of 10 mg per kilogram 
significantly prolonged overall survival and dis-
tant metastasis–free survival as compared with 
Treatment All Patients
Patients Who Had Disease Recurrence 
or Died
Ipilimumab 
(N = 475)
Placebo 
(N = 476)
Ipilimumab 
(N = 264)
Placebo 
(N = 323)
number (percent)
First postprotocol treatment
Chemotherapy 41 (8.6) 53 (11.1) 40 (15.2) 52 (16.1)
Radiotherapy 19 (4.0) 19 (4.0) 19 (7.2) 19 (5.9)
Surgery 47 (9.9) 33 (6.9) 41 (15.5) 31 (9.6)
Chemoradiotherapy 1 (0.2) 4 (0.8) 1 (0.4) 4 (1.2)
Biologic‑response modifier 48 (10.1) 88 (18.5) 48 (18.2) 86 (26.6)
Combination therapy 13 (2.7) 22 (4.6) 12 (4.5) 22 (6.8)
Other 37 (7.8) 36 (7.6) 33 (12.5) 36 (11.1)
No treatment reported 269 (56.6) 221 (46.4) 70 (26.5) 73 (22.6)
Ipilimumab 24 (5.1) 76 (16.0) 24 (9.1) 76 (23.5)
Anti–PD‑1 agent 25 (5.3) 30 (6.3) 24 (9.1) 30 (9.3)
BRAF inhibitor 65 (13.7) 88 (18.5) 63 (23.9) 88 (27.2)
*  Percentages may not total 100 because of rounding. PD‑1 denotes programmed death 1.
Table 2. Postprotocol Treatment in All the Patients Who Underwent Randomization and in Those Who Had Disease 
Recurrence or Died.*
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placebo. The risk of death was 28% lower with 
ipilimumab than with placebo, and the risk of 
distant metastasis or death was lower by 24%. At 
5 years, ipilimumab treatment was associated 
with rates that were approximately 10 percent-
age points higher than the rates with placebo for 
all end points: recurrence-free survival (40.8% 
vs. 30.3%), overall survival (65.4% vs. 54.4%), and 
distant metastasis–free survival (48.3% vs. 38.9%). 
The results show that at the cost of substantial 
toxic effects, the previously observed prolonga-
tion of recurrence-free survival with ipilimumab 
is confirmed in the current updated analysis and 
that it translated into a prolongation in overall 
survival and distant metastasis–free survival.
Despite successful treatment with surgery (fol-
lowed by adjuvant therapy in patients at high 
risk for disease recurrence), only approximately 
45% of patients with stage III melanoma will be 
disease-free after 4 years; less than 40% of pa-
tients who have surgery alone will be disease-free 
after 4 years.17 Interferon alfa is currently approved 
in both the United States and the European 
Union for the treatment of stage III melanoma 
after surgery. In a literature-based meta-analysis 
of 17 randomized, controlled trials involving 
8122 patients with high-risk cutaneous mela-
noma, interferon alfa prolonged the time to re-
currence (hazard ratio for disease recurrence with 
interferon alfa vs. observation, 0.82).15 Owing to 
the marginal benefit in overall survival (hazard 
ratio for death, 0.89) and the considerable toxic 
Figure 2. Forest Plot for Overall Survival, According to Trial Group.
Results are expressed as unstratified hazard ratios for the risk of death in the ipilimumab group as compared with the placebo group 
with 95% confidence intervals for the analysis of the total group and with 99% confidence intervals for all the subgroup analyses. The 
size of the box is proportional to the total number of deaths reported in each subgroup, the diamond is centered on the overall hazard 
ratio for death and covers its 95% confidence interval, and the dashed line represents the overall hazard ratio for death. The P value for 
the univariate analysis that included all patients was provided by the unstratified log‑rank test. The P value for the analysis of heteroge‑
neity between the hazard ratios computed within the subgroups of a given variable was provided by the test of heterogeneity (see the 
Supplementary Appendix). The disease stage, according to the case‑report forms, was determined with the use of the American Joint 
Committee on Cancer 2002 criteria. The number of positive lymph nodes was determined by means of pathological testing. Additional 
information is provided in Figure S4A in the Supplementary Appendix.
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effects, interferon alfa is not widely used as an 
adjuvant therapy.18 Although the benefit–risk pro-
file of interferon alfa as compared with ipilimu-
mab remains unclear, a phase 3 trial (ECOG 1609) 
that directly compares interferon alfa with ipilimu-
mab at a dose of 3 or 10 mg per kilogram in pa-
tients with resected stage III or IV melanoma is 
ongoing (ClinicalTrials.gov number, NCT01274338). 
In our trial (EORTC 18071), patients were treated 
for up to 3 years, but only 13.4% of the patients 
completed this treatment period and 40% had 
stopped ipilimumab treatment at the end of the 
first four doses over the first 3 months. Thus, 
the EORTC 18071 trial cannot address whether 
maintenance treatment is necessary.
In the current trial, the survival benefit of 
ipilimumab over placebo was generally consistent 
across subgroups. This benefit was observed not 
only in patients with microscopic involvement 
only (sentinel node–positive) but also in patients 
with macroscopic or palpable nodes. In contrast, 
in previous EORTC trials of adjuvant therapy in 
patients with melanoma,17,19-22 a significant bene-
fit with interferon alfa was observed only in pa-
tients with microscopic involvement. Similarly, 
in contrast to interferon alfa, for which ulceration 
is the overriding determinant of activity,13,17,20-23 
ipilimumab prolonged survival among patients 
with nonulcerated melanoma and among those 
with ulcerated melanoma.
The rate of adverse events with ipilimumab in 
the context of adjuvant therapy was substantial 
and led to the discontinuation of treatment in 
approximately 40% of the patients by the end of 
the initial dosing period (i.e., before maintenance 
therapy). This frequency is higher than that ob-
served with the same dose in the pooled analysis 
involving patients with advanced melanoma.2-4 
The vast majority of immune-related adverse events 
of grade 2, 3, or 4 resolved within 4 to 8 weeks 
with the use of established management guide-
lines. However, for endocrinopathies, the median 
time to resolution was 54 weeks, and 48.5% of 
the patients who had endocrinopathy continue 
to take hormone-replacement therapies. In this 
trial, adjuvant therapy with ipilimumab was as-
Event Ipilimumab (N = 471) Placebo (N = 474)
Any Grade Grade 3 Grade 4 Grade 5 Any Grade Grade 3 Grade 4 Grade 5
Any immune‑related adverse 
event
426 (90.4) 169 (35.9) 27 (5.7) 5 (1.1) 188 (39.7) 12 (2.5) 1 (0.2) 0
Any dermatologic event 298 (63.3) 20 (4.2) 0 0 99 (20.9) 0 0 0
Rash 161 (34.2) 5 (1.1) 0 0 52 (11.0) 0 0 0
Any gastrointestinal event† 217 (46.1) 70 (14.9) 6 (1.3) 3 (0.6) 85 (17.9) 3 (0.6) 1 (0.2) 0
Diarrhea 194 (41.2) 46 (9.8) 0 0 80 (16.9) 2 (0.4) 0 0
Colitis 73 (15.5) 32 (6.8) 4 (0.8) 3 (0.6) 7 (1.5) 1 (0.2) 1 (0.2) 0
Any endocrine‑system event 178 (37.8) 34 (7.2) 3 (0.6) 0 38 (8.0) 1 (0.2) 0 0
Hypophysitis 77 (16.3) 20 (4.2) 1 (0.2) 0 1 (0.2) 0 0 0
Any hepatic event 115 (24.4) 38 (8.1) 13 (2.8) 0 20 (4.2) 1 (0.2) 0 0
Increase in liver‑enzyme 
levels
83 (17.6) 14 (3.0) 6 (1.3) 0 18 (3.8) 0 0 0
Any neurologic event 21 (4.5) 5 (1.1) 4 (0.8) 0 9 (1.9) 0 0 0
Other‡ 111 (23.6) 34 (7.2) 2 (0.4) 2 (0.4) 23 (4.9) 8 (1.7) 0 0
*  The safety analysis included all the patients who underwent randomization and received at least one dose of ipilimumab or placebo (945 
 patients). Immune‑related adverse events that occurred in at least 10% of the patients are reported. Patients may have had more than one 
event. In the ipilimumab group, 5 patients died because of drug‑related adverse events; 3 patients died from colitis (2 patients with gastro‑
intestinal perforation), 1 from myocarditis, and 1 from multiorgan failure associated with the Guillain–Barré syndrome.
†  Gastrointestinal perforation occurred in seven patients (1.5%) in the ipilimumab group (all such events were considered to be related to 
 ipilimumab) and in three patients (0.6%) in the placebo group (none of these events were considered to be related to placebo).
‡  In the ipilimumab group, 26 patients had a grade 3 or 4 lipase level, 4 had a grade 3 or 4 immune‑system disorder (hypersensitivity, auto‑
immune disorder, anaphylactoid reaction, or drug hypersensitivity), 4 had grade 3 lung infiltration, pneumonitis, or interstitial lung disease, 
1 had arthritis, and 1 had uveitis.
Table 3. Immune-Related Adverse Events.*
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sociated with a higher risk and greater degree of 
diarrhea, insomnia, and fatigue than placebo 
during the induction period, but ipilimumab did 
not have a negative effect on the global health 
scale of health-related quality of life.12
Of concern are the five patients (1.1%) in the 
ipilimumab group who died owing to drug-related 
adverse events. In the context of adjuvant ther-
apy, the benefit–risk profile is particularly im-
portant in view of the prognostic heterogeneity 
observed in patients with stage III melanoma.
In conclusion, adjuvant ipilimumab was asso-
ciated with clinical improvements and signifi-
cantly prolonged overall survival and distant 
metastasis–free survival, as compared with pla-
cebo, among patients with high-risk stage III 
melanoma, thus extending previous findings of 
a prolongation of recurrence-free survival. Adverse 
events were common but mostly transient. Some 
adverse events were serious, and even death 
from treatment occurred despite the use of es-
tablished treatment algorithms.
 Dr. Eggermont reports receiving fees for serving on scientific 
advisory boards from Actelion Pharmaceuticals, Agenus, Bristol-
Myers Squibb, GlaxoSmithKline, HalioDx, Incyte, Merck Sharp 
& Dohme, Novartis, and Pfizer; Dr. Chiarion-Sileni, receiving 
consulting fees and travel support from Bristol-Myers Squibb, 
Roche, GlaxoSmithKline, and Merck Sharp & Dohme, and lec-
ture fees from Bristol-Myers Squibb, Roche, and GlaxoSmith-
Kline; Dr. Grob, receiving consulting fees from Bristol-Myers 
Squibb, GlaxoSmithKline, Novartis, Roche, Merck, and Amgen, 
lecture fees from Bristol-Myers Squibb, GlaxoSmithKline, and 
Roche, travel support from Roche, and research funding from 
Bristol-Myers Squibb and Roche; Dr. Dummer, receiving con-
sulting fees, honoraria, and research funding from Bristol-
Myers Squibb, Roche, GlaxoSmithKline, Merck Sharp & Dohme, 
and Novartis; Dr. Wolchok, receiving consulting fees from Bristol-
Myers Squibb, Merck, MedImmune, Ziopharm Oncology, Poly-
noma, Polaris, GlaxoSmithKline, and Jounce Therapeutics, 
honoraria from EMD Serono and Janssen Oncology, institu-
tional research funding from Bristol-Myers Squibb, Merck, 
MedImmune, and GlaxoSmithKline, and holding a pending 
patent related to compositions and methods for the treatment of 
melanoma (U.S. patent number, US7556805); Dr. Hamid, receiv-
ing consulting fees from Amgen, Novartis, Roche, Bristol-Myers 
Squibb, Merck, Merck Serono, Pfizer, and Genentech, and lec-
ture fees from Novartis, Bristol-Myers Squibb, and Genentech; 
Dr. Robert, receiving consulting fees from Bristol-Myers Squibb, 
Merck, Roche, and Amgen, and honoraria from Bristol-Myers 
Squibb, Merck, GlaxoSmithKline, Roche, Novartis, and Amgen; 
Dr. Ascierto, receiving consulting fees from Bristol-Myers Squibb, 
Roche (formerly Genentech), GlaxoSmithKline, Merck Sharp & 
Dohme, Ventana Medical Systems, Novartis, and Amgen, hono-
raria from Bristol-Myers Squibb, Roche (formerly Genentech), 
and GlaxoSmithKline, and grant support to his institution from 
Bristol-Myers Squibb, Roche (formerly Genentech), and Ventana 
Medical Systems; Dr. Lebbé, receiving fees for serving on advi-
sory boards from Bristol-Myers Squibb, Merck Sharp & Dohme, 
Roche, GlaxoSmithKline, and Novartis; Dr. Smylie, receiving 
consulting fees and honoraria from Bristol-Myers Squibb, Roche, 
GlaxoSmithKline, and Merck, and lecture fees from Bristol-Myers 
Squibb and Roche; Dr. Weber, receiving consulting fees and 
honoraria from Bristol-Myers Squibb, Merck, GlaxoSmithKline, 
Roche, and Genentech, research funding from Bristol-Myers 
Squibb, Merck, GlaxoSmithKline, Roche, and Genentech, and 
MacroGenics, and holding stock in Celldex Therapeutics, Altor 
BioScience, and cCAM Biotherapeutics; Dr. Maio, receiving con-
sulting fees, honoraria, and travel support from Bristol-Myers 
Squibb, Merck Sharp & Dohme, Roche, GlaxoSmithKline, and 
MedImmune, and research funding from Bristol-Myers Squibb 
and MedImmune; Dr. Bastholt, receiving fees for serving on 
advisory boards from Bristol-Myers Squibb, Merck Sharp & 
Dohme, Roche, and GlaxoSmithKline; Dr. Mortier, receiving 
fees for serving on an advisory board from Bristol-Myers Squibb 
and clinical-trial support from Bristol-Myers Squibb, Glaxo-
SmithKline, Merck Sharp & Dohme, and Roche; Dr. Hauschild, 
receiving consulting fees and honoraria from Amgen, Bristol-
Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Med-
Immune, Nektar Therapeutics, OncoSec Medical, Philogen, 
Provectus Biopharmaceuticals, and Regeneron Pharmaceuticals, 
and grant support from Amgen, Bristol-Myers Squibb, Celgene, 
Eisai, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, 
Novartis, and Roche; Dr. Hassel, receiving consulting fees from 
GlaxoSmithKline and Amgen, honoraria and lecture fees from 
Bristol-Myers Squibb, GlaxoSmithKline, Roche, Merck Sharp & 
Dohme, and Amgen, and travel support from Bristol-Myers 
Squibb and Amgen; Dr. Hodi, receiving consulting fees and 
grant support to his institution from Bristol-Myers Squibb, hold-
ing a patent related to therapeutic peptides (U.S. patent number, 
20160046716), and holding a pending patent related to methods 
for treating MHC class I polypeptide-related sequence A (MICA) 
related disorders (U.S. patent number, 20140037630); Dr. Taitt 
and Ms. de Pril, being employees of Bristol-Myers Squibb; and 
Dr. Taitt, holding stock in Bristol-Myers Squibb. No other poten-
tial conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank all the team members at the European Organiza-
tion for Research and Treatment of Cancer (EORTC) headquar-
ters, including Isabelle Blangenois, Sandra Collette, Valérie De-
waste, Thierry Gorlia, Sven Janssen, Niels Lema, Larissa Polders, 
and Simon Vanderschaeghe, for contributions to the trial; the 
team members at Bristol-Myers Squibb (in particular, Chantal 
Lejeune); and Ward Pedersen, of StemScientific, for editorial as-
sistance with an earlier version of the manuscript.
Appendix
The authors’ full names and academic degrees are as follows: Alexander M.M. Eggermont, M.D., Ph.D., Vanna Chiarion-Sileni, M.D., 
Jean-Jacques Grob, M.D., Ph.D., Reinhard Dummer, M.D., Jedd D. Wolchok, M.D., Ph.D., Henrik Schmidt, M.D., Omid Hamid, 
M.D., Caroline Robert, M.D., Ph.D., Paolo A. Ascierto, M.D., Jon M. Richards, M.D., Céleste Lebbé, M.D., Ph.D., Virginia Ferraresi, 
M.D., Michael Smylie, M.D., Jeffrey S. Weber, M.D., Ph.D., Michele Maio, M.D., Ph.D., Lars Bastholt, M.D., Laurent Mortier, M.D., Ph.D., 
Luc Thomas, M.D., Ph.D., Saad Tahir, M.D., Axel Hauschild, M.D., Ph.D., Jessica C. Hassel, M.D., F. Stephen Hodi, M.D., Corina 
Taitt, M.D., Veerle de Pril, M.Sc., Gaetan de Schaetzen, Ph.D., Stefan Suciu, Ph.D., and Alessandro Testori, M.D.
The authors’ affiliations are as follows: Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix–Marseille Uni-
versity, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University 
Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV LIBRARY OF SOUTHERN DENMARK on September 8, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;19 nejm.org November 10, 2016 1855
Prolonged Survival in Stage III Melanoma with Ipilimumab
(L.T.) — all in France; the Oncology Institute of Veneto–Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto 
Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, 
Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) — all in Italy; University of Zurich Hospital, 
Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and 
Odense University Hospital, Odense (L.B.) — both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology 
Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL 
(J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig–Holstein, Kiel (A.H.), and University 
Hospital Heidelberg, Heidelberg (J.C.H.) — both in Germany; Dana–Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Prince-
ton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).
References
1. Hodi FS, O’Day SJ, McDermott DF, et 
al. Improved survival with ipilimumab in 
patients with metastatic melanoma. N Engl 
J Med 2010; 363: 711-23.
2. Robert C, Thomas L, Bondarenko I, et 
al. Ipilimumab plus dacarbazine for pre-
viously untreated metastatic melanoma. 
N Engl J Med 2011; 364: 2517-26.
3. Wolchok JD, Neyns B, Linette G, et al. 
Ipilimumab monotherapy in patients with 
pretreated advanced melanoma: a random-
ised, double-blind, multicentre, phase 2, 
dose-ranging study. Lancet Oncol 2010; 
11: 155-64.
4. Schadendorf D, Hodi FS, Robert C, et 
al. Pooled analysis of long-term survival 
data from phase II and phase III trials of 
ipilimumab in unresectable or metastatic 
melanoma. J Clin Oncol 2015; 33: 1889-
94.
5. Eggermont AMM, Spatz A, Robert C. 
Cutaneous melanoma. Lancet 2014; 383: 
816-27.
6. Balch CM, Gershenwald JE, Soong S-J, 
et al. Final version of 2009 AJCC melano-
ma staging and classification. J Clin On-
col 2009; 27: 6199-206.
7. Balch CM, Gershenwald JE, Soong S-J, 
et al. Multivariate analysis of prognostic 
factors among 2,313 patients with stage III 
melanoma: comparison of nodal micro-
metastases versus macrometastases. J Clin 
Oncol 2010; 28: 2452-9.
8. van Akkooi ACJ, Nowecki ZI, Voit C, et 
al. Sentinel node tumor burden according 
to the Rotterdam criteria is the most im-
portant prognostic factor for survival in 
melanoma patients: a multicenter study 
in 388 patients with positive sentinel 
nodes. Ann Surg 2008; 248: 949-55.
9. van der Ploeg APT, van Akkooi ACJ, 
Rutkowski P, et al. Prognosis in patients 
with sentinel node-positive melanoma is 
accurately defined by the combined Rot-
terdam tumor load and Dewar topogra-
phy criteria. J Clin Oncol 2011; 29: 2206-
14.
10. van der Ploeg APT, van Akkooi ACJ, 
Haydu LE, et al. The prognostic signifi-
cance of sentinel node tumour burden in 
melanoma patients: an international, 
multicenter study of 1539 sentinel node-
positive melanoma patients. Eur J Cancer 
2014; 50: 111-20.
11. Eggermont AM, Chiarion-Sileni V, 
Grob JJ, et al. Adjuvant ipilimumab versus 
placebo after complete resection of high-
risk stage III melanoma (EORTC 18071): 
a randomised, double-blind, phase 3 trial. 
Lancet Oncol 2015; 16: 522-30.
12. Coens C, Suciu S, Vanna Chiarion- 
Sileni V, et al. Phase III trial (EORTC 
18071/CA184-029) of post-operative adju-
vant ipilimumab compared to placebo in 
patients with resected stage III cutaneous 
melanoma: health related quality of life 
(HRQoL) results. Lancet Oncol (in press).
13. Suciu S, Ives N, Eggermont AM, et al. 
Predictive importance of ulceration on the 
efficacy of adjuvant interferon-a (IFN): an 
individual patient data (IPD) meta-analy-
sis of 15 randomized trials in more than 
7,500 melanoma patients (pts). J Clin On-
col 2014; 32: Suppl:5s. abstract.
14. Wheatley K, Ives N, Hancock B, Gore 
M, Eggermont A, Suciu S. Does adjuvant 
interferon-alpha for high-risk melanoma 
provide a worthwhile benefit? A meta-
analysis of the randomised trials. Cancer 
Treat Rev 2003; 29: 241-52.
15. Mocellin S, Pasquali S, Rossi CR, 
Nitti D. Interferon alpha adjuvant therapy 
in patients with high-risk melanoma: 
a systematic review and meta-analysis. 
J Natl Cancer Inst 2010; 102: 493-501.
16. Pocock SJ, Simon R. Sequential treat-
ment assignment with balancing for prog-
nostic factors in the controlled clinical 
trial. Biometrics 1975; 31: 103-15.
17. Eggermont AM, Suciu S, Rutkowski P, 
et al. Long term follow up of the EORTC 
18952 trial of adjuvant therapy in resected 
stage IIB-III cutaneous melanoma pa-
tients comparing intermediate doses of 
interferon-alpha-2b (IFN) with observa-
tion: ulceration of primary is key determi-
nant for IFN-sensitivity. Eur J Cancer 
2016; 55: 111-21.
18. Garbe C, Peris K, Hauschild A, et al. 
Diagnosis and treatment of melanoma: 
European consensus-based interdisciplin-
ary guideline — update 2016. Eur J Cancer 
2016; 63: 201-17.
19. Eggermont AMM, Suciu S, MacKie R, 
et al. Post-surgery adjuvant therapy with 
intermediate doses of interferon alfa 2b 
versus observation in patients with stage 
IIb/III melanoma (EORTC 18952): random-
ised controlled trial. Lancet 2005; 366: 
1189-96.
20. Eggermont AMM, Suciu S, Santinami 
M, et al. Adjuvant therapy with pegylated 
interferon alfa-2b versus observation alone 
in resected stage III melanoma: final re-
sults of EORTC 18991, a randomised 
phase III trial. Lancet 2008; 372: 117-26.
21. Eggermont AM, Suciu S, Testori A, et 
al. Long-term results of the randomized 
phase III trial EORTC 18991 of adjuvant 
therapy with pegylated interferon alfa-2b 
versus observation in resected stage III 
melanoma. J Clin Oncol 2012; 30: 3810-8.
22. Eggermont AMM, Suciu S, Testori A, 
et al. Ulceration and stage are predictive 
of interferon efficacy in melanoma: results 
of the phase III adjuvant trials EORTC 
18952 and EORTC 18991. Eur J Cancer 
2012; 48: 218-25.
23. Eggermont AM, Spatz A, Lazar V, 
Robert C. Is ulceration in cutaneous mela-
noma just a prognostic and predictive fac-
tor or is ulcerated melanoma a distinct 
biologic entity? Curr Opin Oncol 2012; 24: 
137-40.
Copyright © 2016 Massachusetts Medical Society.
receive immediate notification when an article  
is published online first
To be notified by e-mail when Journal articles  
are published Online First, sign up at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV LIBRARY OF SOUTHERN DENMARK on September 8, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
